J H Frederik Falkenburg (Jh Frederik Falkenburg)

ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 8

Top Venues

Oncoimmunology

Blood

Cancer immunology, immunotherapy : CII

Cancer immunology research

lumc (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

lumc

Netherlands

PHD :: hematology

Publications

Kyra J Fuchs, Marian van de Meent, M Willy Honders, Indu Khatri, Michel G D Kester, Eva A S Koster, Georgia Koutsoumpli, Arnoud H de Ru, Cornelis A M van Bergen, Peter A van Veelen, Peter A C 't Hoen, Peter van Balen, Erik Ben van den Akker, Joan Hendrik Veelken, Constantijn Jm Jm Halkes, J H Frederik Falkenburg, Marieke Griffioen
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens. Blood 143 (18) (2024)
Kyra J Fuchs, Marian van de Meent, M Willy Honders, Indu Khatri, Michel G D Kester, Eva A S Koster, Georgia Koutsoumpli, Arnoud H de Ru, Cornelis A M van Bergen, Peter A van Veelen, Peter A C 't Hoen, Peter van Balen, Erik Ben van den Akker, Joan Hendrik Veelken, Constantijn Jm Jm Halkes, J H Frederik Falkenburg, Marieke Griffioen
Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens. Blood 143 (18) (2024)
Sietse J Luk, Rouven Schoppmeyer, Marieke E Ijsselsteijn, Antonios Somarakis, Ibtissam Acem, Dennis F G Remst, Daan T Cox, Cornelis A M van Bergen, Inge H Briaire-de Bruijn, Max L B Grönloh, Werner J van der Meer, Lukas J A C Hawinkels, Roman I Koning, Erik Bos, Judith V M G Bovée, Noel F C C de Miranda, Károly Szuhai, Jaap Diederik van Buul, J H Frederik Falkenburg, Mirjam H M Heemskerk
VISTA expression on cancer-associated endothelium selectively prevents T-cell extravasation. Cancer immunology research (2023)
Tassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, Renate S Hagedoorn, Miranda H Meeuwsen, Eline van Diest, Jeanette H W Leusen, Jürgen H E Kuball, J H Frederik Falkenburg, Mirjam H M Heemskerk
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. Oncoimmunology 11 (1) (2022)
Jesper van Eck van der Sluijs, Diede van Ens, Soley Thordardottir, Denise Vodegel, Inge A T Hermens, Anniek B van der Waart, J H Frederik Falkenburg, Michel G D Kester, Iris de Rink, Mirjam H M Heemskerk, Jannie Borst, Nicolaas P M Schaap, Joop H Jansen, Yanling Xiao, Harry Dolstra, Willemijn Hobo
Clinically applicable CD34+-derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. Cancer immunology, immunotherapy : CII 70 (11) (2021)
Charlotte M Mousset, Willemijn Hobo, Yun Ji, Hanny Fredrix, Valeria De Giorgi, Robert D Allison, Michel G D Kester, J H Frederik Falkenburg, Nicolaas P M Schaap, Joop H Jansen, Luca Gattinoni, Harry Dolstra, Anniek B van der Waart
Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. Oncoimmunology 7 (10) (2018)
Sietse J Luk, Dirk M van der Steen, Renate S Hagedoorn, Ekaterina S Jordanova, Marco W Schilham, Judith V M G Bovée, Arjen Hg Cleven, J H Frederik Falkenburg, Károly Szuhai, Mirjam Hm Heemskerk
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy. Oncoimmunology 7 (12) (2018)
Cor H J Lamers, Rebecca Wijers, Cornelis A M van Bergen, Judith A E Somers, Eric Braakman, Jan Willem Gratama, Reno Debets, J H Frederik Falkenburg, Jan J Cornelissen
CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation. Blood 128 (17) (2016)

J H Frederik Falkenburg.css-eqlu8i{font-size:small;padding-left:4px;} (Jh Frederik Falkenburg)

Publication Activity (10 Years)

Top Topics

Top Venues

J H Frederik Falkenburg (Jh Frederik Falkenburg)